An EASL-Framed Review of Clinical, Regulatory, and Access Drivers

EASL–EASD–EASO’s 2024 guidance positions MASH care around structured, noninvasive risk stratification (FIB-4 → VCTE or ELF) and emphasizes treating the highest-risk, noncirrhotic fibrotic population (≥F2) while awaiting robust outcomes data for broader adoption and for cirrhosis-stage “MASH-targeted” therapy 232. The category has been defined clinically and regulatorily by resmetirom (Rezdiffra)—FDA accelerated approval in March 2024 and EU conditional approval in August 2025—both anchored on 12‑month biopsy surrogate endpoints with required confirmatory evidence generation 12529. Market formation is now increasingly shaped by (i) payer/HTA requirements for noninvasive test (NIT) gating and renewal, (ii) affordability concerns in large prevalent populations, and (iii) uneven national HTA conclusions despite centralized EU authorization 3140.

1. EASL guidance as the organizing lens: diagnosis, stratification, and who should be treated

1.1 Diagnostic and risk stratification framework

The EASL–EASD–EASO 2024 guideline recommends a stepwise risk stratification pathway in which FIB-4 is used first (because it is inexpensive and widely available) and then VCTE (transient elastography) and/or the Enhanced Liver Fibrosis (ELF) test are applied sequentially to refine risk and predict progression 23. In resource-constrained settings, ultrasonography is highlighted as an accessible first-line screen for hepatic steatosis, with fibrosis assessment then prioritized via FIB-4 followed by VCTE or ELF for higher specificity 2.

EASL frames “case finding” around cardiometabolic risk: noninvasive algorithms should be applied in individuals with cardiometabolic risk factors, abnormal liver enzymes, and/or radiologic steatosis—particularly those with type 2 diabetes (T2D) and obesity with additional metabolic risk factors 23.

1.2 Treatment posture: pharmacotherapy for noncirrhotic fibrotic MASH, not (yet) for cirrhosis

A key EASL pivot (reflecting the first approvals) is a conditional recommendation to consider resmetirom for adults with noncirrhotic MASH and significant fibrosis (≥F2), dependent on local regulatory approval and label 23. In the same guidance, EASL explicitly states: “No MASH-targeted pharmacotherapy can currently be recommended for the cirrhotic stage.” 23

Lifestyle and comorbidity management remain central: Mediterranean diet, 7–10% weight loss targets in those with excess weight, smoking cessation, and alcohol abstinence when significant fibrosis is present 2. EASL also supports use of metabolic agents (e.g., incretin-based therapies, pioglitazone, SGLT‑2 inhibitors) tailored to diabetes/obesity status and liver phenotype, alongside consideration of bariatric surgery in appropriate obesity contexts 2.

1.3 Alignment vs AASLD (practical implications for development and access)

AASLD 2023/2024 also supports a sequential NIT strategy: FIB-4 first, then VCTE or ELF, with explicit cutoffs for triage and follow-up frequency by metabolic risk 24. AASLD provides concrete thresholds—e.g., FIB‑4 <1.3 low risk; 1.3–2.67 intermediate; >2.67 high risk; and age adjustments (>65 years: cutoff >2.0) 24. AASLD also details VCTE and ELF prognostic cutoffs (e.g., ELF ≥9.8 as higher risk; ELF ≥11.3 linked to decompensation risk) 24.

Where the guidelines materially diverge in today’s market is label-driven pharmacotherapy: AASLD’s document (published before the FDA approval) states there were no FDA-approved drugs for NASH and therefore focuses on off-label/adjunctive options with histologic signals in selected groups (vitamin E, pioglitazone, GLP‑1 agents) 24. EASL 2024/2025, updated in the approval era, explicitly incorporates resmetirom for noncirrhotic ≥F2 disease while still withholding “MASH-targeted” recommendations for cirrhosis 23.

2. Category-defining endpoints and trial design

2.1 The two “approval-supporting” biopsy surrogate endpoints

Across pivotal programs and regulatory decisions, MASH trials center on liver biopsy endpoints at ~12 months:

• MASH/NASH resolution without worsening of fibrosis
• ≥1-stage fibrosis improvement without worsening of steatohepatitis (or “no worsening of MASH”)
  These endpoints are explicitly embedded in the EMA’s intermediate endpoint definitions for conditional approval consideration (effective October 1, 2024) 27 and are the basis of resmetirom’s accelerated approval package in the US 129.

2.2 Noninvasive tests (NITs): from triage tools to trial enrichment and payer gating

EASL and AASLD both treat NITs as central to real-world pathway design (primary care → specialist referral), typically using FIB-4 first-line and VCTE/ELF second-line 2324. The evidence base supporting NIT use has expanded:

Regulatory-grade validation (trial enrichment / diagnosis):
The FNIH‑NIMBLE Stage 1 validation evaluated multiple circulating biomarker panels in 1,073 NAFLD participants. NIS4 achieved AUROC 0.81 for “at-risk NASH” (NASH + NAS≥4 + ≥F2) and outperformed ALT and FIB‑4 3. For fibrosis staging, ELF and FibroMeter VCTE outperformed FIB‑4 across ≥F2, ≥F3, and F4 endpoints (e.g., FibroMeter VCTE AUROC up to 0.897 for cirrhosis) 3. These data are explicitly positioned as steps toward regulatory qualification of biomarkers 35.

Meta-analytic performance for “at-risk MASH” screening:
An individual participant data meta-analysis reported AUROCs for identifying MASH+F2–F4 and related targets; a sequential FIB‑4 + LSM‑VCTE strategy reduced the number of elastography exams needed without compromising performance, though sensitivity and “screen failure rate” trade-offs were highlighted 6.

Implementation friction and population screening limits:
A large EHR-based analysis (PCORnet) found that among undiagnosed patients, data insufficiency prevented calculating FIB‑4/NFS in ~68–76%, and one-third of NAFLD-cirrhosis patients still fell into low/intermediate FIB‑4 ranges—underscoring why unselected population screening is problematic and why structured case finding is emphasized 7.

Why NIT choice changes epidemiology and budgets:
NHANES-based modeling showed estimated “NASH prevalence” varies widely by NIT and cutoff (e.g., FAST 1.3–4.8% vs FIB‑4 0.4–12.3%), meaning payer and system burden estimates can swing substantially based on the chosen identification strategy 8.

3. Major MoAs in development

Tool-retrieved pipeline mapping shows a crowded landscape across four core mechanistic classes—THR‑β agonists, FXR agonists, PPAR agonists, and incretin-based therapies (GLP‑1 and multi-agonists)—with numerous Phase I–III programs globally (notably USA, EU, and China) 21.

3.1 THR‑β agonists (metabolic “liver-directed” fat reduction)

Resmetirom is a partial thyroid hormone receptor‑β activator that reduces liver fat accumulation, with GI adverse events (diarrhea, nausea) and warnings for hepatotoxicity and gallbladder events; important drug interactions exist, particularly with statins 1. Multiple THR‑β competitors are in mid-stage development (e.g., VK‑2809 and others) 21, reinforcing a thesis that liver-selective metabolic modulation can be a durable backbone therapy in ≥F2 noncirrhotic disease.

3.2 FXR agonists / bile acid pathway modulation (metabolic + inflammatory signaling)

FXR agonism has been pursued for anti-fibrotic and metabolic effects; the class includes late-stage historical programs (e.g., obeticholic acid) and newer assets, including combinations 21. Class-specific tolerability issues (notably pruritus and lipid changes in some programs) have been central to differentiation strategies in development discussions 22.

3.3 PPAR agonists (systemic metabolic rewiring; pan- vs selective)

PPAR agonists (including pan-PPAR) have pursued combined metabolic and inflammatory improvements; lanifibranor and elafibranor represent prominent Phase III-stage efforts in the retrieved landscape 21. Practical positioning depends on balancing metabolic benefit with tolerability (e.g., weight gain/edema signals in some PPAR approaches discussed in trial landscape summaries) 22.

3.4 GLP‑1 receptor agonists and multi-agonists (weight loss as MASH therapy, plus direct liver effects)

GLP-1 monotherapy and incretin multi-agonists remain central to the field. Semaglutide progressed from Phase III development to FDA approval for noncirrhotic MASH with moderate-to-advanced fibrosis in August 2025, while tirzepatide has shown positive Phase II biopsy-based results and remains an important investigational program. The class is clinically important because it spans both metabolic comorbidity management and, now in semaglutide’s case, liver-specific regulatory approval 21.

3.5 Combination therapy logic—and barriers

Mechanistically, MASH is a convergence of steatosis, inflammation, and fibrosis, which motivates combinations (e.g., metabolic + anti-fibrotic). The retrieved development landscape includes multiple combination efforts (e.g., FXR + other pathways; PPAR + SGLT2; GLP‑1 combinations in preclinical settings) 21. Practical barriers include chronic tolerability, overlapping adverse events, and more complex regulatory and payer evidence demands for combinations (e.g., demonstrating additive benefit over monotherapy).

4. Pivotal data readouts and near-term catalysts

4.1 Resmetirom as the benchmark (and the “proof of regulatory acceptability”)

The FDA approved resmetirom (Rezdiffra) on March 14, 2024 for adults with noncirrhotic NASH/MASH with moderate-to-advanced fibrosis alongside diet and exercise, via accelerated approval based on a 12‑month biopsy surrogate endpoint in a long (54‑month) randomized trial 1. At 12 months, biopsy readouts showed:

• NASH resolution / no worsening of fibrosis: 26–27% (80 mg) and 24–36% (100 mg) vs 9–13% placebo
• Fibrosis improvement with no NASH worsening: 23% (80 mg) and 24–28% (100 mg) vs 13–15% placebo
  Ranges reflected inter-pathologist variability 1.

In the EU, the European Commission granted conditional marketing authorization on 18 August 2025 for noncirrhotic MASH with F2–F3 fibrosis, following a positive CHMP opinion (June 2025) 252628. EMA product materials similarly report ~26–30% MASH resolution and ~27–29% fibrosis improvement (dose-dependent) versus placebo at 12 months, with diarrhea and nausea most common; the authorization requires ongoing study results and annual review 28.

4.2 Broader clinical landscape signals (selected highlights from retrieved trial summaries)

The retrieved pivotal-trial landscape synthesis emphasizes that successful Phase 2b/3 programs tend to show ~20–30% NASH resolution and ~20–40% fibrosis improvement over 12–24 months as “category benchmarks,” with safety often dominated by GI tolerability (incretins), pruritus (some FXR approaches), and metabolic trade-offs (some PPAR approaches) 22. It also highlights expanding interest in longer trials and in compensated cirrhosis (F4) programs, though EASL does not yet recommend MASH-targeted pharmacotherapy for cirrhosis-stage disease 2322.

5. Regulatory milestones and pathways: FDA accelerated approval vs EMA conditional approval

5.1 FDA accelerated approval: surrogate endpoints + mandatory confirmation

Resmetirom’s FDA approval is explicitly accelerated and contingent on verification of clinical benefit in a confirmatory outcomes trial. The FDA approval letter specifies the ongoing MAESTRO‑NASH OUTCOMES trial with expected completion August 2028 and final report submission March 2029, evaluating progression to cirrhosis, hepatic decompensation, transplant, and mortality 29. The FDA also required multiple postmarketing studies (pediatrics, pregnancy/lactation exposure, renal impairment PK) and heightened hepatotoxicity pharmacovigilance reporting early post-approval 29.

5.2 EMA conditional approval: intermediate endpoints, staged evidence generation

The EMA’s April 2024 reflection paper signals willingness to consider conditional approval based on intermediate endpoints for both noncirrhotic F2–F3 and cirrhotic F4 disease, explicitly defining acceptable endpoints as (i) MASH resolution without fibrosis worsening and (ii) ≥1-stage fibrosis improvement without worsening of MASH components 27. Resmetirom’s subsequent EU conditional authorization reflects this framework in practice, paired with formal obligations to submit additional long-term data 28.

6. Commercial access: HTA and payer constraints are now “category-shaping”

6.1 US value assessment and affordability pressure (ICER)

ICER’s 2023 final evidence report set health-benefit price benchmarks of $39,600–$50,100/year for resmetirom (and $32,600–$40,400 for obeticholic acid) and issued an affordability alert given the very large eligible population 31. ICER’s budget-impact modeling suggested only ~6.5% of eligible patients/year could be treated with resmetirom before exceeding its budget impact threshold, underscoring why payers are likely to restrict access initially to higher-risk segments 31. ICER also recommended insurers avoid universal biopsy requirements, favoring NIT-based pathways (FIB‑4 plus FibroScan/MRE) and specialist-led initiation, with monitoring at 12–18 months using noninvasive measures rather than mandatory biopsy 31.

6.2 NICE and UK context: guidance updates and technology appraisal in flight

NICE’s 2024 surveillance concluded that NAFLD guidance requires updating due to significant new evidence and system need 4. NICE is also running a technology appraisal for resmetirom and semaglutide in noncirrhotic MASH with moderate-to-advanced fibrosis; as of March 2026, this appraisal remains in progress (scoping/engagement stages; publication date TBC) 32.

6.3 EU reality: centralized authorization, divergent national value judgments

Despite EU-wide conditional approval for resmetirom, Germany’s IQWiG dossier assessment concluded “added benefit not proven”, and the G‑BA decision (05‑03‑2026) confirmed that conclusion—citing concerns including concomitant therapy restrictions in trials and generalizability issues 40. This is a concrete example of how national HTA can slow or constrain uptake even after EU authorization.

6.4 US payer controls: NIT gating, specialist prescribing, and renewal based on response

Concrete payer policy examples in the retrieved materials show that coverage is being operationalized through:

• Fibrosis stage confirmation (F2–F3) by biopsy or elastography/MRE
• Specialist prescribing (hepatology/gastroenterology)
• Documented metabolic risk-factor burden
  Kansas Medicaid draft PA criteria (effective April 2025) required F2–F3 confirmation by biopsy or VCTE/MRE thresholds, plus ≥3 metabolic risk factors and lifestyle intervention participation; renewals required response evidence (e.g., ≥25% VCTE stiffness reduction or ≥20% MRE stiffness reduction, or histologic response) 29.
  AvMed’s PA policy similarly required F2–F3 evidence by biopsy or elastography and specialist involvement, but notably included a step requirement of an unsuccessful 6‑month Wegovy trial (semaglutide for obesity) with documentation of insufficient MASH response—illustrating payer heterogeneity and the potential for “metabolic-first” step edits in some plans 50.

6.5 The operational bottleneck: test selection, cutoffs, and real-world pathway adherence

A global survey of 321 providers found TE and FIB‑4 were most used, but cutoffs varied widely, confirmatory strategies differed (one vs two NITs vs biopsy), and only ~65% reported following professional guideline recommendations—highlighting a major implementation gap as pharmacotherapy scales 14. At the system level, EHR data incompleteness and indeterminate-zone limitations can blunt population-level risk stratification, reinforcing EASL/AASLD’s preference for targeted case finding in high-risk groups rather than general screening 72324.

7. 12–24 month milestone watchlist (selected, based on retrieved materials)

Scope and evidence limits (from retrieved materials)

This review only reflects what was available in the provided tool results. For example, detailed, payer-specific PA PDFs for major PBMs (CVS Caremark, Express Scripts, OptumRx, UHC, Anthem) were not retrieved; only general form portals and one detailed commercial-plan example (AvMed) were captured 5052. Likewise, country-by-country EU reimbursement decisions beyond Germany were not available in the retrieved sources 40.